← Eichor
Condition: Multiple Sclerosis Chronic Progressive Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Multiple Sclerosis Chronic Progressive

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Bringing the Outdoors In: Virtual Nature Walks for Depression in Multiple Sclerosis (MS) Patients
NA · 1 location(s) · University of Michigan · NCT07392879Impact of the Cionic Neural Sleeve on Mobility in Multiple Sclerosis
NA · 1 location(s) · Cionic, Inc. · NCT05964829A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of a New Subcuta
Phase 1 · 12 location(s) · Hoffmann-La Roche · NCT07667322A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis
Phase 3 · 40 location(s) · Zenas BioPharma (USA), LLC · NCT07067463Development of Camera Based Gait Quality Measure for Persons With Multiple Sclerosis
Phase N/A · 1 location(s) · Shirley Ryan AbilityLab · NCT06516458Effects of Transcranial Static Magnetic Field Stimulation (tSMS) in Progressive Multiple Sclerosis
NA · 1 location(s) · Neuromed IRCCS · NCT05811013A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell ( CAR-T) Therapy in Subjects With Non-relapsing and Progressive Fo
Phase 1 · 1 location(s) · Stanford University · NCT06138132Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)
Phase 3 · 22 location(s) · National Institute of Allergy and Infectious Diseases (NIAID · NCT04047628"Selfie" Videos: A Novel, Patient-centered, Comprehensive Approach to Measuring Function in MS
Phase N/A · 1 location(s) · University of California, San Francisco · NCT07222618Effects of Acute Intermittent Hypoxia on Neuroplasticity in MS
NA · 1 location(s) · Shirley Ryan AbilityLab · NCT06390930Imaging the Interplay Between Axonal Damage and Repair in Multiple Sclerosis
Phase N/A · 1 location(s) · University Hospital, Basel, Switzerland · NCT05177523MS-ResearchBiomarkerS
Phase N/A · 1 location(s) · Cedars-Sinai Medical Center · NCT05204459Targeting Residual Activity By Precision, Biomarker-Guided Combination Therapies of Multiple Sclerosis (TRAP-MS)
Phase 1/Phase 2 · 1 location(s) · National Institute of Allergy and Infectious Diseases (NIAID · NCT03109288Nicotinamide Riboside Supplementation In Progressive Multiple Sclerosis
Phase 2 · 1 location(s) · Haukeland University Hospital · NCT05740722Definition of Autonomic Nervous System Involvement in Patients With Multiple Sclerosis
NA · 2 location(s) · Istituti Clinici Scientifici Maugeri SpA · NCT05748015A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis
Phase 3 · 236 location(s) · Novartis Pharmaceuticals · NCT07225504Intermittent Hypoxia in Persons With Multiple Sclerosis
NA · 1 location(s) · Shirley Ryan AbilityLab · NCT06276634Assessing Changes in Multi-parametric MRI in MS Patients Taking Clemastine Fumarate as a Myelin Repair Therapy
Phase 1/Phase 2 · 1 location(s) · University of California, San Francisco · NCT05359653A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders
Phase 1 · 8 location(s) · TG Therapeutics, Inc. · NCT06680037Open-label, Multi-center, Phase I/II Study to Assess Safety, Disease Progression and Cellular Kinetics Following YTB323
Phase 1/Phase 2 · 18 location(s) · Novartis Pharmaceuticals · NCT06675864A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489 as Add-on Therapy to Ocrel
Phase 2 · 103 location(s) · Hoffmann-La Roche · NCT07282574Treatment of Participants With Primary or Secondary Progressive Multiple Sclerosis
Phase 1/Phase 2 · 2 location(s) · Tr1X, Inc. · NCT07477639The Effect of Rituximab on Cognitive and Hand Functions in Secondary Progressive Multiple Sclerosis
Phase 2 · 1 location(s) · Cairo University · NCT06599307Home Based Functional Balance Intervention for Multiple Sclerosis
NA · 1 location(s) · University of Illinois at Chicago · NCT07355387Cladribine vs Placebo for Non-active Progressive Multiple Sclerosis (CLASP-MS).
Phase 2/Phase 3 · 1 location(s) · Institute of Psychiatry and Neurology, Warsaw · NCT05961644Allogenic Adipose Tissue-derived Mesenchymal Stromal Cells for the Treatment of Primary Progressive Multiple Sclerosis
Phase 1 · 2 location(s) · Rennes University Hospital · NCT06592703Cognitive Performance, Sleep Disturbances and Fatigue in Multiple Sclerosis
Phase N/A · 2 location(s) · Heinrich-Heine University, Duesseldorf · NCT07426991Phase 1 Study of HBI0101 CAR-T in Refractory B-Cell Autoimmune Diseases
Phase 1 · 1 location(s) · Polina Stepensky · NCT07085676SIZOMUS Safety of Ixazomib Targeting Plasma Cells in Multiple Sclerosis
Phase 1 · 1 location(s) · Queen Mary University of London · NCT03783416Obe-cel in Refractory Progressive Forms of Multiple Sclerosis
Phase 1 · 7 location(s) · Autolus Limited · NCT07139743
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.